Optimization of Emulsion PCR for Aptamer Selection
Location
King Building 343
Document Type
Presentation
Start Date
4-28-2017 4:30 PM
End Date
4-28-2017 5:50 PM
Abstract
Cancers are known to produce unique biomolecules or biomarkers that can be detected using diagnostic tests. CA-125 and HE4 are two biomarkers used in clinical tests to detect ovarian cancer, which responds favorably to treatment when diagnosed at its earliest stage. These tests however, often produce both false positives, identifying cancer when it is not present, and false negatives, failing to detect biomarkers that are present. A diagnostic test based on recognition by nucleic acid aptamers may help improve detection of these biomarkers. SELEX is one method used to select aptamers, short oligonucleotides, (usually RNA or single stranded DNA) that bind to a target with high affinity and specificity. The selection process requires PCR to amplify the aptamers. At high cycle numbers, the use of PCR with aptamers is problematic due to byproduct formation and low yields of double stranded DNA (dsDNA). Emulsion PCR (ePCR) has been found to reduce byproducts at high cycle numbers through the use of an oil and water mixture. The emulsion reduces the aqueous phase to tiny droplets, creating individual reaction chambers which produce dsDNA with reduced byproduct. ePCR using a EurX kit has reliably produced dsDNA with less byproduct compared to conventional PCR. Successful optimization of ePCR will be used in the next SELEX selection of HE4.
Keywords:
ovarian cancer, cancer detection, aptamers, DNA
Recommended Citation
Schuster-Little, Naviya, "Optimization of Emulsion PCR for Aptamer Selection" (04/28/17). Senior Symposium. 62.
https://digitalcommons.oberlin.edu/seniorsymp/2017/presentations/62
Major
Biochemistry
Advisor(s)
Manish Mehta, Chemistry & Biochemistry
Project Mentor(s)
Rebecca Whelan, Chemistry & Biochemistry
April 2017
Optimization of Emulsion PCR for Aptamer Selection
King Building 343
Cancers are known to produce unique biomolecules or biomarkers that can be detected using diagnostic tests. CA-125 and HE4 are two biomarkers used in clinical tests to detect ovarian cancer, which responds favorably to treatment when diagnosed at its earliest stage. These tests however, often produce both false positives, identifying cancer when it is not present, and false negatives, failing to detect biomarkers that are present. A diagnostic test based on recognition by nucleic acid aptamers may help improve detection of these biomarkers. SELEX is one method used to select aptamers, short oligonucleotides, (usually RNA or single stranded DNA) that bind to a target with high affinity and specificity. The selection process requires PCR to amplify the aptamers. At high cycle numbers, the use of PCR with aptamers is problematic due to byproduct formation and low yields of double stranded DNA (dsDNA). Emulsion PCR (ePCR) has been found to reduce byproducts at high cycle numbers through the use of an oil and water mixture. The emulsion reduces the aqueous phase to tiny droplets, creating individual reaction chambers which produce dsDNA with reduced byproduct. ePCR using a EurX kit has reliably produced dsDNA with less byproduct compared to conventional PCR. Successful optimization of ePCR will be used in the next SELEX selection of HE4.
Notes
Session III, Panel 20 - Water | Health
Moderator: Marcelo Vinces, Director, Center for Learning, Education, and Research (CLEAR) in the Sciences; Associate Director, Center for Teaching Innovation and Excellence (CTIE)